Research programme- cancer therapeutics - Proteros Biostructures/ Merck

Drug Profile

Research programme- cancer therapeutics - Proteros Biostructures/ Merck

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteros Biostructures
  • Developer Merck Sharp & Dohme; Proteros Biostructures
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 22 Nov 2016 Proteros Biostructures and Merck Sharp & Dohme enter into a second collaboration for epigenetic drug discovery for Cancer
  • 30 Dec 2015 Proteros Biostructures and Merck Sharp & Dohme enter into a collaboration for epigenetic drug discovery for Cancer
  • 30 Dec 2015 Early research in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top